SAFETY DATA SHEET Based on Directive 2001/58/EC of the Commission of the European Communities PROGESTERONE Identification of the substance/preparation and of the company/undertaking 1.1 Identification of the substance or preparation: Synonyms: : 57-83-0 Reference number : EC index No. NFPA code : 0-1-0(*) Molecular weight Formula : 1.2 Use of the substance or the preparation:
Certified reference material for laboratory use only
1.3 Company/undertaking identification:
Institute for Reference Materials and Measurements
1.4 Telephone number for emergency:
p/a Militair Hospitaal Koningin Astrid, Bruynstraat 1, B-1120 Brussel
Composition/information on ingredients Hazardous ingredients Conc. in Hazard EINECS/ELINCS No. (R-phrases)
(1) For R-phrases in full: see heading 16
3. Hazards identification
- Limited evidence of a carcinogenic effect
First aid measures 4.1 Eye contact:
- Consult a doctor/medical service if irritation persists
4.2 Skin contact:
- Consult a doctor/medical service if irritation persists
4.3 After inhalation:
- Consult a doctor/medical service if breathing problems develop
- Unconscious: maintain adequate airway and respiration
4.4 After ingestion:
- Consult a doctor/medical service if you feel unwell
- Never give water to an unconscious person
: 11-2005
: Brandweerinformatiecentrum voor Gevaarlijke Stoffen vzw (BIG)
Technische Schoolstraat 43 A, B-2440 Geel
PROGESTERONE 5. Fire-fighting measures 5.1 Suitable extinguishing media: 5.2 Unsuitable extinguishing media: 5.3 Special exposure hazards: 5.4 Instructions:
- No specific firefighting instructions required
5.5 Special protective equipment for firefighters:
- Heat/fire exposure: compressed air/oxygen apparatus
- Protective clothing for exposure to chemicals
Accidental release measures 6.1 Personal protection/precautions: 6.2 Environmental precautions: 6.3 Methods for cleaning up:
- Scoop solid spill into closing containers
- Clean contaminated surfaces with an excess of water
- Wash clothing and equipment after handling
Handling and storage 7.1 Handling: 7.2 Storage:
- Keep away from: heat sources, ignition sources, oxidizing agents
temperature Quantity Materials for packaging 7.3 Specific uses:
- See information supplied by the manufacturer
: 11-2005 PROGESTERONE Exposure controls/Personal protection 8.1 Exposure limit values: TLV-STEL TLV-Ceiling OES-LTEL OES-STEL MEL-LTEL MEL-STEL MAC-TGG 8 h : not listed MAC-TGG 15 min. : not listed MAC-Ceiling Momentary Sampling methods: 8.2 Exposure controls: 8.2.1 Occupational exposure controls:
- Measure the concentration in the air regularly
8.2.2 Environmental exposure controls: see heading 13 8.3 Personal protection: 8.3.1 respiratory protection:
- Dust production: dust mask with filter type P2
8.3.2 hand protection: 8.3.3 eye protection:
- In case of dust production: protective goggles
8.3.4 skin protection:
: 11-2005 PROGESTERONE Physical and chemical properties 9.1 General information: 9.2 Important health, safety and environmental information: vol% ( °C)
0.00088 g/100 ml 9.3 Other information: 10. Stability and reactivity 10.1 Conditions to avoid/reactivity: 10.2 Materials to avoid:
- Keep away from: heat sources, ignition sources, oxidizing agents
10.3 Hazardous decomposition products:
: 11-2005 PROGESTERONE 11. Toxicological information 11.1 Acute toxicity: LD50 oral rat LD50 dermal rat
: N.D. mg/kg LD50 dermal rabbit
: N.D. mg/kg LC50 inhalation rat : N.D. mg/l/4 LC50 inhalation rat : N.D. 11.2 Chronic toxicity: EC carc. cat. EC muta. cat. : not listed EC repr. cat. : not listed Carcinogenicity (TLV) : not listed Carcinogenicity (MAC) : not listed Carcinogenicity (VME) : not listed Carcinogenicity (GWBB): not listed Carcinogenicity (MAK) : not listed Mutagenicity (MAK) : not listed Teratogenicity (MAK) IARC classification
11.3 Routes of exposure: 11.4 Acute effects/symptoms: AFTER INGESTION
- Change in the haemogramme/blood composition
AFTER SKIN CONTACT 11.5 Chronic effects:
- No certainty about human carcinogenic properties
- Not listed in mutagenicity class (EC,MAK)
- Not classified as toxic to reproduction (EC)
: 11-2005 PROGESTERONE 12. Ecological information 12.1 Ecotoxicity:
12.2 Mobility: Volatile organic compounds (VOC): 0%
For other physicochemical properties see heading 9
12.3 Persistence and degradability:
- biodegradation BOD5 : : T ½: N.D. 12.4 Bioaccumulative potential: 12.5 Other adverse effects:
- Effect on the ozone layer
- Greenhouse effect
- Effect on waste water purification 13. Disposal considerations 13.1 Provisions relating to waste:
- Waste material code (91/689/EEC, Council Decision 2001/118/EC, O.J. L47 of
16/2/2001): 16 05 06* (laboratory chemicals, consisting of or containing
dangerous substances, including mixtures of laboratory chemicals)
13.2 Disposal methods:
- Remove to an authorized incinerator equipped with an afterburner and a flue
13.3 Packaging/Container:
- Waste material code packaging (91/689/EEC, Council Decision 2001/118/EC,
O.J. L47 of 16/2/2001): 15 01 10* (packaging containing residues of or
: 11-2005 PROGESTERONE 14. Transport information 14.1 Classification of the substance in compliance with UN Recommendations PROPER SHIPPING NAME 14.2 ADR (transport by road) : NOT SUBJECT DANGER LABEL TANKS DANGER LABEL PACKAGES 14.3 RID (transport by rail) : NOT SUBJECT DANGER LABEL TANKS DANGER LABEL PACKAGES 14.4 ADNR (transport by inland waterways) : NOT SUBJECT DANGER LABEL TANKS DANGER LABEL PACKAGES 14.5 IMDG (maritime transport) : NOT SUBJECT POLLUTANT 14.6 ICAO (air transport) : NOT SUBJECT PACKING INSTRUCTIONS PASSENGER AIRCRAFT PACKING INSTRUCTIONS CARGO AIRCRAFT 14.7 Special precautions in connection with : not restricted for any mode of transport 15. Regulatory information
Not listed in Annex I of directive 67/548/EEC et sequens. Labelling
established on the basis of the available data.
(1) Limited evidence of a carcinogenic effect
(1) Wear suitable protective clothing and gloves
(1) (If swallowed, seek medical advice immediately and show
(1) Does not need to be mentioned on packages < 125 ml
: 11-2005 PROGESTERONE 16. Other information
The information provided on this MSDS is correct to the best of our knowledge, information and belief
at the date of its publication. The information given is designed only as a guidance for safe
handling, use, processing, storage, transportation, disposal and release and is not to be considered
as a warranty or quality specification. The information relates only to the specific material
designated and may not be valid for such material used in combination with any other material or in
any process, unless specified in the text.
Exposure limits:
Occupational Exposure Standards - United Kingdom 2003
Maximum Exposure Limits - United Kingdom 2003
Maximale Arbeitsplatzkonzentrationen - Germany 2002
Technische Richtkonzentrationen - Germany 2002
Maximale aanvaarde concentratie - The Netherlands 2004
Valeurs limites de Moyenne d’Exposition - France 1999
Valeurs limites d’Exposition à court terme - France 1999
Grenswaarde beroepsmatige blootstelling - Belgium 2002
Grenswaarde kortstondige blootstelling - Belgium 2002
: Indicative occupational exposure limit values - directive 2000/39/EC
Inhalable fraction = T: Total dust = E: Einatembarer Aerosolanteil
Respirable fraction = A: Alveolengängiger Aerosolanteil/Alveolar dust Chronic toxicity:
List of the carcinogenic substances and processes - The Netherlands 2005
Full text of any R-phrases referred to under heading 2:
: Limited evidence of a carcinogenic effect
: 11-2005
FAHMI ISHAQ EL-URI M.B.Ch.B (Hons), MRCOG, FRCOG Tel +9626 534 2386, Mob +96279 557 1068, E-mail PERSONAL DETAILS QUALIFICATIONS FRCOG, Fellow of the Royal College of Obstetricians& Gynaecologists, London MRCOG, Member of the Royal College of Obstetricians& Gynaecologists, London MBChB (Hons) , Faculty of Medicine, Alexandria University, Egypt French Internatio
Your guide to Type 2 diabetes What is type 2 diabetes? Type 2 diabetes is more common than type 1 diabetes and usually develops in people over the age of 35. It is often associated with being overweight. It tends to run in families and is also more common in people from the Asian community. It is also more common in women who have had diabetes during a pregnancy (Gestational Diabete